摘要
目的探讨慢性乙型肝炎(CHB)患者接受核(苷)酸类似物(NAs)抗病毒治疗后血清乙型肝炎病毒脱氧核糖核酸(HBV-DNA)的表达及临床意义。方法回顾性分析2021年1月至2022年10月河南省人民医院83例采用NAs抗病毒治疗的CHB患者临床资料,根据血清学应答标准将其分为应答组(46例)和未应答组(37例)。比较两组基线资料、治疗前及治疗3、6、12个月时血清HBV-DNA水平;绘制受试者工作特征(ROC)曲线,以曲线下面积(AUC)检验血清HBV-DNA对CHB患者NAs抗病毒治疗未应答的预测价值。结果治疗前,应答组和未应答组HBV-DNA比较,差异无统计学意义(P>0.05);两组治疗前至治疗12个月的HBV-DNA呈下降趋势,组间、时点、交互效应有统计学意义(P<0.05)。绘制ROC曲线显示,治疗3个月时HBV-DNA对CHB患者NAs抗病毒治疗未应答的预测价值较低(AUC=0.694,P=0.002),治疗6个月时HBV-DNA对CHB患者NAs抗病毒治疗未应答具有一定预测价值(AUC=0.751,P<0.001)。结论血清HBV-DNA表达在CHB患者NAs抗病毒治疗前后变化明显,且治疗6个月时血清HBV-DNA可作为抗病毒治疗未应答的预测指标。
Objective To explore the expression and clinical significance of hepatitis B virus deoxyribonucleic acid(HBV-DNA)in chronic hepatitis B(CHB)patients undergoing antiviral therapy with nucleoside analogues and nucleotide analogues(NAs).Methods A retrospective analysis was conducted on the clinical data of 83 CHB patients treated with NAs antiviral therapy at Henan Provincial People’s Hospital from January 2021 to October 2022.According to the serological response criteria,they were divided into response group(46 cases)and non-response group(37 cases).Baseline data and serum HBV-DNA levels before treatment,at 3,6 and 12 months of treatment were compared between two groups.The receiver operating characteristic(ROC)curve was drawn,and the area under the curve(AUC)was used to test the predictive value of serum HBV-DNA for non-response to NAs antiviral therapy in CHB patients.Results Before treatment,there was no statistical difference in HBV-DNA between the response group and the non-response group(P>0.05).The HBV-DNA of the two groups showed a gradual downward trend from before treatment to 12 months after treatment.The inter group,time point,and interaction effects had statistical significance(P<0.05).The ROC curve showed that the predictive value of HBV-DNA for non-response to NAs antiviral therapy in CHB patients was low at 3 months of treatment(AUC=0.694,P=0.002),while HBV-DNA had a certain predictive value for non-response to NAs antiviral therapy in CHB patients at 6 months of treatment(AUC=0.751,P<0.001).Conclusion The expression of serum HBV-DNA showed significant changes in CHB patients before and after NAs antiviral therapy,and serum HBV-DNA at 6 months of treatment can serve as a predictive indicator of non-response to antiviral therapy.
作者
李慧
LI Hui(Department of Clinical Laboratory,Henan Provincial People’s Hospital,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2024年第8期1404-1407,共4页
Henan Medical Research
关键词
慢性乙型肝炎
核(苷)酸类似物
抗病毒治疗
乙型肝炎病毒脱氧核糖核酸
chronic hepatitis B
nucleoside analogues and nucleotide analogues
antiviral therapy
hepatitis B virus deoxyribonucleic acid
